Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | TACR1 | P25103 | 4/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MAP2 | P11137 | 2/20 | 0.31 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.30 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.30 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3584470 | 0.94 | MEN1 (0.42) | MEN1KMT2ATACR1HSP90AA1ALDH1A1 | |
| SCHEMBL3588435 | 0.93 | KMT2A (0.36) | MEN1KMT2AHSP90AA1PTGDR2ALDH1A1 | |
| SCHEMBL3587000 | 0.90 | MEN1 (0.40) | MEN1KMT2ATACR1HSP90AA1MAPT | |
| SCHEMBL3588250 | 0.89 | ATM (0.42) | MEN1KMT2AHSP90AA1ALDH1A1ATM | |
| SCHEMBL3582557 | 0.88 | MEN1 (0.41) | MEN1KMT2ATACR1HSP90AA1PTGDR2 | |
| SCHEMBL3586766 | 0.88 | KMT2A (0.38) | MEN1KMT2AHSP90AA1PTGDR2ALDH1A1 | |
| SCHEMBL3586121 | 0.88 | MEN1 (0.44) | MEN1KMT2ATACR1HSP90AA1ALDH1A1 | |
| SCHEMBL3578045 | 0.88 | PTGDR2 (0.35) | PTGDR2MAP2 | |
| SCHEMBL3586897 | 0.87 | KMT2A (0.42) | MEN1KMT2ATACR1HSP90AA1MAPT | |
| SCHEMBL3579793 | 0.84 | CRHBP (0.40) | MEN1KMT2APTGDR2ALDH1A1MAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113421-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | claimed |
| EP-2076492-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2009-07-08 | — | — | EP | claimed |
| WO-2008054605-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-08 | — | — | WO | claimed |
| US-20100113421-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113421-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | RTF1, RNGTT, POLR2E | MEN1 4584/4885KMT2A 1816/4885TACR1 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.